MCID: PNC041
MIFTS: 51

Pancreatic Ductal Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Adenocarcinoma

MalaCards integrated aliases for Pancreatic Ductal Adenocarcinoma:

Name: Pancreatic Ductal Adenocarcinoma 12 15 17 71
Ductal Adenocarcinoma of the Pancreas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3498
NCIt 49 C9120
UMLS 71 C1335302

Summaries for Pancreatic Ductal Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that derives from pancreatic duct cells.

MalaCards based summary : Pancreatic Ductal Adenocarcinoma, also known as ductal adenocarcinoma of the pancreas, is related to pancreatic cancer and cholangiocarcinoma, and has symptoms including pruritus, abdominal pain and icterus. An important gene associated with Pancreatic Ductal Adenocarcinoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Hyaluronic acid and Calcium, Dietary have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, t cells and lymph node.

Related Diseases for Pancreatic Ductal Adenocarcinoma

Diseases related to Pancreatic Ductal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 241)
# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 33.3 UCA1 PVT1 MIR21 MIR155 MALAT1 LINC00673
2 cholangiocarcinoma 31.5 UCA1 MIR21 MALAT1 H19 DAPK1 AFAP1-AS1
3 retinitis pigmentosa 11 31.1 UCA1 PVT1 HOTAIR
4 lung cancer susceptibility 3 31.1 MIR31HG MIR21 MALAT1 HOTAIR H19 DAPK1
5 b-cell lymphoma 31.0 PVT1 MIR21 MIR155 MALAT1 HOTAIR DAPK1
6 kidney cancer 30.8 PVT1 MIR21 MALAT1 HOTAIR H19 DAPK1
7 renal cell carcinoma, nonpapillary 30.8 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTAIR
8 gastrointestinal system cancer 30.8 MIR21 MIR155 MALAT1 HOTAIR H19
9 small cell cancer of the lung 30.7 MIR21 MALAT1 HOTTIP HOTAIR
10 gallbladder cancer 30.7 UCA1 MALAT1 HOTAIR H19 AFAP1-AS1
11 osteogenic sarcoma 30.7 UCA1 TUSC7 PVT1 MALAT1 HOTTIP HOTAIR
12 hepatocellular carcinoma 30.7 UCA1 TUSC7 PVT1 MIR21 MIR155 MALAT1
13 esophageal cancer 30.6 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTTIP
14 nasopharyngeal carcinoma 30.5 PVT1 MIR21 MALAT1 HOTAIR H19 DAPK1
15 leukemia, acute myeloid 30.5 UCA1 TUSC7 MIR21 MIR155 MALAT1 HOTAIRM1
16 clear cell renal cell carcinoma 30.5 PVT1 MIR21 MIR155 MALAT1
17 pituitary adenoma 30.5 MALAT1 HOTAIR H19
18 gastric cancer 30.0 UCA1 TUSC7 TMEM238L PVT1 MIR31HG MIR21
19 colorectal cancer 29.6 UCA1 TUSC7 TMEM238L PVT1 MIR31HG MIR21
20 adenocarcinoma 11.6
21 pancreatic cancer 5 11.5
22 pancreatic adenocarcinoma 11.0
23 pancreatitis 10.8
24 pancreas disease 10.7
25 pancreatic agenesis 1 10.7
26 pancreatic ductal carcinoma 10.7
27 autoimmune pancreatitis 10.7
28 polymyositis 10.6 MIR21 MIR155
29 microvascular complications of diabetes 3 10.6 PVT1 MIR21 MALAT1
30 intrahepatic cholangiocarcinoma 10.6
31 severe combined immunodeficiency 10.6
32 laryngeal squamous cell carcinoma 10.6 MIR21 MIR155 MALAT1 HOTAIR H19
33 triple-receptor negative breast cancer 10.6 MALAT1 HOTAIR
34 thyroid cancer, nonmedullary, 1 10.5 MALAT1 HOTTIP HOTAIR H19
35 neutropenia 10.5
36 vulva squamous cell carcinoma 10.5 MIR31HG MALAT1
37 oral squamous cell carcinoma 10.5 UCA1 MIR21 MIR155 MALAT1 HOTAIR H19
38 myeloma, multiple 10.5 UCA1 PVT1 MIR21 MALAT1 HOTAIR H19
39 tongue disease 10.5 UCA1 MIR21 LINC00673
40 lymphoma, hodgkin, classic 10.5 PVT1 MIR21 MIR155
41 bladder urothelial carcinoma 10.5 UCA1 PVT1 MALAT1 HOTAIR
42 esophagus squamous cell carcinoma 10.5 HOTAIR AFAP1-AS1
43 pancreatitis, hereditary 10.5
44 neuroendocrine tumor 10.5
45 acute pancreatitis 10.5
46 glioma susceptibility 1 10.5 TUSC7 MIR21 MALAT1 HOTAIRM1 HOTAIR H19
47 glioma 10.4 UCA1 PVT1 MIR21 MALAT1 HOTTIP HOTAIR
48 obstructive jaundice 10.4
49 hypoxia 10.4
50 tongue squamous cell carcinoma 10.4 UCA1 MIR21 MALAT1 LINC00673 HOTTIP AFAP1-AS1

Graphical network of the top 20 diseases related to Pancreatic Ductal Adenocarcinoma:



Diseases related to Pancreatic Ductal Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Ductal Adenocarcinoma

UMLS symptoms related to Pancreatic Ductal Adenocarcinoma:


pruritus, abdominal pain, icterus

Drugs & Therapeutics for Pancreatic Ductal Adenocarcinoma

Drugs for Pancreatic Ductal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
2 Calcium, Dietary Phase 3
3
asparaginase Phase 3
4 glucocorticoids Phase 3
5 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3
6
Calcium Nutraceutical Phase 3 7440-70-2 271
7
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
8
Enoxaparin Approved Phase 2 9005-49-6 772
9
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
11
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
12
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
13
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
14
nivolumab Approved Phase 2 946414-94-4
15
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
16
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
17
Atezolizumab Approved, Investigational Phase 1, Phase 2 1380723-44-3
18
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
19
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
20
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
21
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
22
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
23
Propofol Approved, Investigational, Vet_approved Phase 2 2078-54-8 4943
24
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
25
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
26
Pemetrexed Approved, Investigational Phase 1, Phase 2 137281-23-3, 150399-23-8 60843 446556
27
Coal tar Approved Phase 1, Phase 2 8007-45-2
28
leucovorin Approved Phase 2 58-05-9 6006 143
29
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
30
Metformin Approved Phase 2 657-24-9 14219 4091
31
Adenosine Approved, Investigational Phase 2 58-61-7 60961
32
Olaparib Approved Phase 2 763113-22-0 23725625
33
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
34
Durvalumab Approved, Investigational Phase 2 1428935-60-7
35
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
36
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
38
Cediranib Investigational Phase 2 288383-20-0 9933475
39 Misonidazole Investigational Phase 2 13551-87-6
40
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
41
Tremelimumab Investigational Phase 2 745013-59-6
42 Fibrinolytic Agents Phase 2
43 Hormones Phase 2
44
Liposomal doxorubicin Phase 2 31703
45 Antineoplastic Agents, Hormonal Phase 2
46 Antiemetics Phase 2
47 Hormone Antagonists Phase 2
48 Anticoagulants Phase 2
49 acivicin Phase 2
50 Liver Extracts Phase 2

Interventional clinical trials:

(show top 50) (show all 239)
# Name Status NCT ID Phase Drugs
1 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
2 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
3 A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma Recruiting NCT03665441 Phase 3 eryaspase;Gemcitabine plus Abraxane;Irinotecan plus 5-FU plus leucovorin
4 Nordic Multicentre Un-blinded Phase II Randomized Controlled Trial (RCT) Evaluating the Additional Efficacy of Adding Chemotherapy Prior to Resection of a Pancreatic Head Malignancy to Avoid Early Mortality in Those Ultimately Resected Recruiting NCT02919787 Phase 2, Phase 3 5-FU;Oxaliplatine;Irinotecan;5-FU;Oxaliplatine;Irinotecan
5 A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma Recruiting NCT03899636 Phase 3 Modified FOLFIRINOX Regimen
6 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
7 A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT) Not yet recruiting NCT04329949 Phase 3 Relacorilant, 100 mg and 25 mg;Nab paclitaxel
8 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer During Pancreaticoduodenectomy (MAPLE-PD Trial) Not yet recruiting NCT03317886 Phase 3
9 A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma Suspended NCT03943667 Phase 3 Gemcitabine;Paclitaxel
10 A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase Terminated NCT02101021 Phase 3 Momelotinib;Placebo to match momelotinib;Nab-paclitaxel;Gemcitabine
11 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Terminated NCT02715804 Phase 3 Placebo;nab-Paclitaxel;Gemcitabine
12 Phase II Trial of Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Chinese Patients With Advanced Pancreatic Cancer Unknown status NCT02135822 Phase 2 nanoparticle albumin-bound paclitaxel;gemcitabine
13 Phase II Trial of Nab-paclitaxel Plus S-1 in First-line Treatment of Patients With Advanced Pancreatic Cancer Unknown status NCT02124317 Phase 2 nanoparticle albumin-bound paclitaxel;S-1
14 A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of the Combination of S-1, Irinotecan and Oxaliplatin (SIRIOX) in Treating Patients With Advanced Inoperable or Metastatic Pancreatic Cancer Unknown status NCT03403101 Phase 2 S1;Oxaliplatin;Irinotecan
15 PHASE II Study - EFFICACY AND SAFETY OF PARPi TO TREAT PANCREATIC CANCER Unknown status NCT02511223 Phase 2 OLAPARIB
16 A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
17 A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
18 An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02981342 Phase 2 Abemaciclib;LY3023414;Gemcitabine;Capecitabine
19 A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02289898 Phase 2 Demcizumab;Abraxane®;gemcitabine;Placebo
20 A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Completed NCT01893801 Phase 1, Phase 2 nab-paclitaxel;Cisplatin;gemcitabine
21 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Completed NCT00585078 Phase 2 Capecitabine;Oxaliplatin
22 Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Completed NCT02440958 Phase 2 modified FOLFIRINOX regimen
23 A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy Completed NCT01580397 Phase 2 INNO-206
24 Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel (Abraxane) Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT03529175 Phase 2 Abraxane (nab-paclitaxel);Gemcitabine
25 A Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors Completed NCT02880371 Phase 1, Phase 2 ARRY-382;Pembrolizumab
26 A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer Completed NCT01839487 Phase 2 PEGPH20;Nab-paclitaxel;Gemcitabine;Dexamethasone;Enoxaparin
27 A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
28 A Phase II Study of S-1 in Combination With Gemcitabine and Erlotinib in Patients With Advanced or Metastatic Pancreatic Cancer Completed NCT01693419 Phase 2 GES (Gemcitabine, Erlotinib, S-1)
29 A Pilot Study of Neoadjuvant and Adjuvant mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma Completed NCT01660711 Phase 2 5 Fluorouracil;Leucovorin;Irinotecan;Oxaliplatin
30 A Phase II Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03915444 Phase 2 nab-Paclitaxel + Cisplatin + Gemcitabine
31 Phase 2 Study Evaluating the Efficacy,Safety,Tolerability and PK of siG12D-LODER in the Treatment of Patients With Unresectable LAPC When Used in Conjunction With Standard Chemotherapy (Gemcitabine+Nab-Paclitaxel) Versus Chemotherapy Alone Recruiting NCT01676259 Phase 2 siG12D-LODER;Gemcitabine+nab-Paclitaxel
32 A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT03727880 Phase 2 Pembrolizumab;Defactinib
33 A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM - D17-01 PRODIGE 63 Study). Recruiting NCT03806309 Phase 2 FOLFIRI;OSE2101;Nivolumab
34 A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs). Recruiting NCT03767582 Phase 1, Phase 2 Nivolumab;CCR2/CCR5 dual antagonist;GVAX
35 Phase II Trial Comparing Nab-paclitaxel Plus S-1 Versus Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Patients With Advanced Pancreatic Cancer Recruiting NCT03636308 Phase 2 nanoparticle albumin-bound paclitaxel;S1;Gemcitabine
36 Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions Recruiting NCT03486327 Phase 2 BR55
37 A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT03496662 Phase 1, Phase 2 BMS-813160;Nivolumab;Gemcitabine;Nab-paclitaxel
38 A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02754726 Phase 2 Nivolumab;Albumin-bound paclitaxel;Paricalcitol;Cisplatin;Gemcitabine
39 PARPVAX: Parpvax: A Phase 1b/2, Open Label Study of Niraparib Plus Either Ipilimumab or Nivolumab in Patients With Advanced Pancreatic Cancer Whose Disease Has Not Progressed on Platinum-based Therapy Recruiting NCT03404960 Phase 1, Phase 2 Niraparib + Nivolumab;Niraparib + Ipilimumab
40 Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Metastatic Pancreatic Adenocarcinoma (ALIX) Recruiting NCT03974854 Phase 2 XELOXIRI-3;Gemcitabine
41 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Recruiting NCT03193190 Phase 1, Phase 2 Nab-Paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Fluorouracil;Atezolizumab;Cobimetinib;PEGPH20;BL-8040;Selicrelumab;Bevacizumab;RO6874281;AB928;Tiragolumab
42 A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRINOX Recruiting NCT04010552 Phase 2 NALRINOX combination
43 A Multicenter, Phase I/II Study of Sequential Epigenetic and Immune Targeting in Combination With Nab-Paclitaxel/Gemcitabine in Patients With Advanced Pancreatic Ductal Adenocarcinoma. Recruiting NCT04257448 Phase 1, Phase 2 Romidepsin;Azacitidine;nab-Paclitaxel;Gemcitabine;Durvalumab;Lenalidomide capsule
44 A Phase II Pilot Trial Of Paclitaxel Protein Bound and Gemcitabine Based Chemotherapy and the Addition Of Paricalcitol Upon Attainment of Stable or Progressive Disease in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT04054362 Phase 2 Paclitaxel protein bound;Cisplatin;Gemcitabine;Paricalcitol
45 Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates Recruiting NCT02723331 Phase 2 Nab-paclitaxel and gemcitabine for R-PDAC Patients;Nab-paclitaxel and gemcitabine for BR-PDAC Patients
46 An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1 Recruiting NCT03525392 Phase 1, Phase 2 177Lu-3BP-227 (also called 177Lu-IPN01087)
47 Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03610490 Phase 2 Cyclophosphamide;Fludarabine
48 Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer Recruiting NCT03977233 Phase 2 Oxaliplatin;Leucovorin;Irinotecan Hydrochloride;5-FU
49 Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer Recruiting NCT03498326 Phase 2 Gemcitabine;Gemcitabine
50 A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy: An AIO Phase II Cross Over Trial (PANTHEON) Recruiting NCT03331640 Phase 2 OFF;FOLFIRI Protocol

Search NIH Clinical Center for Pancreatic Ductal Adenocarcinoma

Genetic Tests for Pancreatic Ductal Adenocarcinoma

Anatomical Context for Pancreatic Ductal Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Ductal Adenocarcinoma:

40
Pancreas, T Cells, Lymph Node, Liver, Neutrophil, Testes, Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Ductal Adenocarcinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Ducts Affected by disease

Publications for Pancreatic Ductal Adenocarcinoma

Articles related to Pancreatic Ductal Adenocarcinoma:

(show top 50) (show all 8146)
# Title Authors PMID Year
1
Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. 61 46
21088996 2011
2
MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. 46 61
21068491 2010
3
MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. 46 61
20093556 2010
4
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. 61 46
19723895 2009
5
Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. 61 46
18719196 2008
6
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. 46 61
17237814 2007
7
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. 46
19551852 2010
8
Heparan sulfate targeting strategy for enhancing liposomal drug accumulation and facilitating deep distribution in tumors. 61
32241176 2020
9
Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer. 61
32510550 2020
10
Six-dimensional quantitative DCE MR Multitasking of the entire abdomen: Method and application to pancreatic ductal adenocarcinoma. 61
31961967 2020
11
Hedgehog signaling promotes angiogenesis directly and indirectly in pancreatic cancer. 61
32444947 2020
12
Triptolide inhibits pancreatic cancer cell proliferation and migration via down-regulating PLAU based on network pharmacology of Tripterygium wilfordii Hook F. 61
32464191 2020
13
Hypoxia and pancreatic ductal adenocarcinoma. 61
32380129 2020
14
Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma. 61
32548230 2020
15
Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. 61
32491160 2020
16
Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia. 61
32344015 2020
17
PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. 61
32422575 2020
18
CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer. 61
32456796 2020
19
Microglia in the hypothalamus respond to tumor-derived factors and are protective against cachexia during pancreatic cancer. 61
32039522 2020
20
Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. 61
32145343 2020
21
Early detection of pancreatic cancer. 61
32135127 2020
22
Proteomic Analysis of Metastasis-Specific Biomarkers in Pancreatic Cancer: Galectin-1 Plays an Important Metastatic Role in Pancreatic Cancer. 61
32413824 2020
23
The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma. 61
32322419 2020
24
Overexpression of MYEOV predicting poor prognosis in patients with pancreatic ductal adenocarcinoma. 61
32420813 2020
25
Fucosyltransferase 8 plays a crucial role in the invasion and metastasis of pancreatic ductal adenocarcinoma. 61
31950256 2020
26
Prognostic significance of p16 protein in pancreatic ductal adenocarcinoma. 61
32499915 2020
27
Association between aberrant dynein cytoplasmic 1 light intermediate chain 1 expression levels, mucins and chemosensitivity in colorectal cancer. 61
32319648 2020
28
The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. 61
31997125 2020
29
Nitric oxide-induced stromal depletion for improved nanoparticle penetration in pancreatic cancer treatment. 61
32247201 2020
30
Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. 61
31837005 2020
31
Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation. 61
32428833 2020
32
Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. 61
32052299 2020
33
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. 61
32541325 2020
34
Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects-results from the POUDER pilot study. 61
31250356 2020
35
Efficient Gene Therapy of Pancreatic Cancer via a Peptide Nucleic Acid (PNA)-Loaded Layered Double Hydroxides (LDH) Nanoplatform. 61
32406198 2020
36
KLF7 promotes pancreatic cancer growth and metastasis by up-regulating ISG expression and maintaining Golgi complex integrity. 61
32430335 2020
37
The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. 61
32517661 2020
38
Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity. 61
32503944 2020
39
Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. 61
32550755 2020
40
Validation of American Joint Committee on Cancer 8th edition of TNM staging in resected distal pancreatic cancer. 61
32550043 2020
41
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. 61
32451495 2020
42
Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. 61
32314446 2020
43
Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. 61
32504777 2020
44
An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. 61
32533886 2020
45
Clinical impact of pancreaticoduodenectomy for pancreatic cancer with resection of the secondary or later branches of the superior mesenteric vein. 61
32563216 2020
46
Expression of classical HLA class I antigens, HLA-E, and HLA-G is adversely prognostic in pancreatic cancer patients. 61
32495519 2020
47
Discovery of new targets to control metastasis in pancreatic cancer by single cell transcriptomics analysis of circulating tumor cells. 61
32499301 2020
48
Increased expression of plakoglobin is associated with upregulated MAPK and PI3K/AKT signalling pathways in early resectable pancreatic ductal adenocarcinoma. 61
32382352 2020
49
Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Investigation. 61
32499156 2020
50
CircFOXK2 Promotes Growth and Metastasis of Pancreatic Ductal Adenocarcinoma by Complexing with RNA-Binding Proteins and Sponging MiR-942. 61
32217695 2020

Variations for Pancreatic Ductal Adenocarcinoma

Copy number variations for Pancreatic Ductal Adenocarcinoma from CNVD:

7 (show top 50) (show all 315)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14616 1 109662726 110421733 Loss Pancreatic ductal adenocarcinoma
2 14979 1 111694621 112653686 Loss Pancreatic ductal adenocarcinoma
3 15141 1 11296895 11700048 Loss Pancreatic ductal adenocarcinoma
4 15254 1 113902673 114772618 Loss Pancreatic ductal adenocarcinoma
5 21071 1 156591077 157602759 Gain Pancreatic ductal adenocarcinoma
6 22927 1 16990962 17780550 Loss Pancreatic ductal adenocarcinoma
7 23665 1 172632928 173462394 Gain Pancreatic ductal adenocarcinoma
8 23983 1 174098656 174792564 Gain Pancreatic ductal adenocarcinoma
9 24268 1 17780550 18767187 Loss Pancreatic ductal adenocarcinoma
10 25340 1 18767187 19870518 Loss Pancreatic ductal adenocarcinoma
11 25429 1 189012940 189640525 Gain Pancreatic ductal adenocarcinoma
12 25525 1 190940606 191897513 Gain Pancreatic ductal adenocarcinoma
13 25603 1 191897513 192833019 Gain Pancreatic ductal adenocarcinoma
14 25668 1 192833019 193928417 Gain Pancreatic ductal adenocarcinoma
15 25957 1 195125528 196179631 Gain Pancreatic ductal adenocarcinoma
16 26123 1 197274194 198251428 Gain Pancreatic ductal adenocarcinoma
17 26286 1 19870518 21264484 Loss Pancreatic ductal adenocarcinoma
18 27649 1 210637543 211466127 Gain Pancreatic ductal adenocarcinoma
19 29512 1 232834654 234059648 Gain Pancreatic ductal adenocarcinoma
20 29988 1 23881482 24596143 Loss Pancreatic ductal adenocarcinoma
21 30783 1 24596143 24901021 Loss Pancreatic ductal adenocarcinoma
22 31049 1 24901021 26202341 Loss Pancreatic ductal adenocarcinoma
23 31229 1 26202341 27453508 Loss Pancreatic ductal adenocarcinoma
24 31475 1 27702974 28279739 Loss Pancreatic ductal adenocarcinoma
25 31649 1 29154418 29949616 Loss Pancreatic ductal adenocarcinoma
26 31710 1 29949616 31202941 Loss Pancreatic ductal adenocarcinoma
27 31822 1 31202941 32179980 Loss Pancreatic ductal adenocarcinoma
28 32104 1 33581730 34569385 Loss Pancreatic ductal adenocarcinoma
29 32211 1 34569385 35804738 Loss Pancreatic ductal adenocarcinoma
30 32498 1 36953732 37599763 Loss Pancreatic ductal adenocarcinoma
31 32649 1 38143717 38830556 Loss Pancreatic ductal adenocarcinoma
32 32759 1 3913633 5229374 Loss Pancreatic ductal adenocarcinoma
33 33297 1 44268667 45000776 Loss Pancreatic ductal adenocarcinoma
34 33745 1 47532872 48556325 Loss Pancreatic ductal adenocarcinoma
35 34094 1 5229374 6509870 Loss Pancreatic ductal adenocarcinoma
36 34199 1 53371440 53750907 Loss Pancreatic ductal adenocarcinoma
37 34230 1 53750907 54788971 Loss Pancreatic ductal adenocarcinoma
38 36948 1 8379388 9142502 Loss Pancreatic ductal adenocarcinoma
39 37455 1 9142502 9661749 Loss Pancreatic ductal adenocarcinoma
40 38508 10 103075332 103271952 Gain Pancreatic ductal adenocarcinoma
41 41307 10 15917593 17007248 Gain Pancreatic ductal adenocarcinoma
42 41728 10 22854210 23744923 Gain Pancreatic ductal adenocarcinoma
43 44446 10 57203760 58367659 Gain Pancreatic ductal adenocarcinoma
44 44911 10 64846281 66342495 Gain Pancreatic ductal adenocarcinoma
45 45553 10 72143312 73316160 Loss Pancreatic ductal adenocarcinoma
46 45655 10 73316160 74391172 Gain Pancreatic ductal adenocarcinoma
47 45775 10 74391172 75333936 Gain Pancreatic ductal adenocarcinoma
48 45937 10 75333936 76299818 Gain Pancreatic ductal adenocarcinoma
49 46231 10 79273961 80171344 Loss Pancreatic ductal adenocarcinoma
50 46288 10 80171344 81279277 Loss Pancreatic ductal adenocarcinoma

Expression for Pancreatic Ductal Adenocarcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Pancreatic Ductal Adenocarcinoma patients vs. healthy controls: 35 (show top 50) (show all 375)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SYCN syncollin Pancreas - 8.04 0.000
2 GP2 glycoprotein 2 (zymogen granule membrane) Pancreas - 7.99 0.000
3 ALB albumin Pancreas - 7.95 0.000
4 SERPINI2 serpin peptidase inhibitor, clade I (pancpin), member 2 Pancreas - 7.95 0.000
5 CELA2B chymotrypsin-like elastase family, member 2B Pancreas - 7.74 0.000
6 PNLIPRP1 pancreatic lipase-related protein 1 Pancreas - 7.66 0.000
7 PDIA2 protein disulfide isomerase family A, member 2 Pancreas - 7.53 0.000
8 SPX spexin hormone Pancreas - 7.53 0.000
9 CTRL chymotrypsin-like Pancreas - 7.52 0.000
10 COL10A1 collagen, type X, alpha 1 Pancreas + 7.52 0.000
11 CELP carboxyl ester lipase pseudogene Pancreas - 7.50 0.000
12 COL5A1 collagen, type V, alpha 1 Pancreas + 7.46 0.000
13 SULF1 sulfatase 1 Pancreas + 7.38 0.000
14 CUZD1 CUB and zona pellucida-like domains 1 Pancreas - 7.29 0.000
15 POSTN periostin, osteoblast specific factor Pancreas + 7.24 0.000
16 COL1A1 collagen, type I, alpha 1 Pancreas + 7.17 0.000
17 AQP8 aquaporin 8 Pancreas - 7.14 0.000
18 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 Pancreas + 7.10 0.000
19 COL11A1 collagen, type XI, alpha 1 Pancreas + 7.00 0.000
20 CLPS colipase, pancreatic Pancreas - 6.99 0.000
21 INHBA inhibin, beta A Pancreas + 6.95 0.000
22 CPA2 carboxypeptidase A2 (pancreatic) Pancreas - 6.88 0.000
23 CTRC chymotrypsin C (caldecrin) Pancreas - 6.87 0.000
24 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) Pancreas + 6.86 0.000
25 PLA2G1B phospholipase A2, group IB (pancreas) Pancreas - 6.79 0.001
26 COL3A1 collagen, type III, alpha 1 Pancreas + 6.78 0.000
27 SFRP4 secreted frizzled-related protein 4 Pancreas + 6.76 0.000
28 CELA3A chymotrypsin-like elastase family, member 3A Pancreas - 6.76 0.001
29 GNMT glycine N-methyltransferase Pancreas - 6.74 0.000
30 COL1A2 collagen, type I, alpha 2 Pancreas + 6.72 0.000
31 REG1P regenerating islet-derived 1 pseudogene Pancreas - 6.72 0.000
32 S100P S100 calcium binding protein P Pancreas + 6.67 0.000
33 CELA3B chymotrypsin-like elastase family, member 3B Pancreas - 6.66 0.001
34 CEL carboxyl ester lipase Pancreas - 6.63 0.001
35 CTHRC1 collagen triple helix repeat containing 1 Pancreas + 6.60 0.000
36 CPA1 carboxypeptidase A1 (pancreatic) Pancreas - 6.56 0.001
37 VCAN versican Pancreas + 6.51 0.000
38 TMEM52 transmembrane protein 52 Pancreas - 6.40 0.000
39 REG1B regenerating islet-derived 1 beta Pancreas - 6.35 0.002
40 CTSE cathepsin E Pancreas + 6.30 0.000
41 GLS2 glutaminase 2 (liver, mitochondrial) Pancreas - 6.28 0.000
42 KLK1 kallikrein 1 Pancreas - 6.26 0.000
43 GJB2 gap junction protein, beta 2, 26kDa Pancreas + 6.24 0.000
44 REG3G regenerating islet-derived 3 gamma Pancreas - 6.17 0.000
45 PLAU plasminogen activator, urokinase Pancreas + 6.15 0.000
46 COL5A2 collagen, type V, alpha 2 Pancreas + 6.13 0.000
47 SLC39A5 solute carrier family 39 (zinc transporter), member 5 Pancreas - 6.09 0.000
48 ERP27 endoplasmic reticulum protein 27 Pancreas - 6.07 0.000
49 SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C Pancreas + 6.00 0.000
50 PNLIP pancreatic lipase Pancreas - 5.94 0.004
Search GEO for disease gene expression data for Pancreatic Ductal Adenocarcinoma.

Pathways for Pancreatic Ductal Adenocarcinoma

Pathways related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 UCA1 HOTAIR

GO Terms for Pancreatic Ductal Adenocarcinoma

Biological processes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of activated T cell proliferation GO:0042104 9.26 MIR21 MIR155
2 positive regulation of cardiac muscle hypertrophy GO:0010613 9.16 MIR21 MIR155
3 negative regulation of innate immune response GO:0045824 8.96 MIR21 MIR155
4 negative regulation of regulatory T cell differentiation GO:0045590 8.62 MIR21 MIR155

Sources for Pancreatic Ductal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....